ArticleJournal of clinical medicine2019
Associations between Urinary Advanced Glycation End Products and Cardiometabolic Parameters in Metabolically Healthy Obese Women.
Article in Journal of clinical medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 9 citations in OpenAlex.
- Addition of monosodium glutamate can reduce the oxidative stability of lipids in pork burger patties via early-stage Maillard reaction products formation.Current research in food science · 2025Article
- Analysis of Methylglyoxal Concentration in a Group of Patients with Newly Diagnosed Prediabetes.Biomedicines · 2023Article
- Glyoxalase I is a novel target for the prevention of metabolic derangement.Pharmacology & therapeutics · 2023Review
- Advanced glycation end product signaling and metabolic complications: Dietary approach.World journal of diabetes · 2023Review
- Inhibitory Effects of Myriocin on Non-Enzymatic Glycation of Bovine Serum Albumin.Molecules (Basel, Switzerland) · 2022Article
- Advanced glycation end products and diabetes and other metabolic indicators.Diabetology & metabolic syndrome · 2022Article
- Effectiveness of Early Advanced Glycation End Product Accumulation Testing in the Diagnosis of Diabetes: A Health Risk Factor Analysis Using the Body Mass Index as a Moderator.Frontiers in endocrinology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Advanced glycation end products (AGEs) have been implicated in the pathophysiology of type 2 diabetes and cardiovascular disease. We aimed to determine the associations of urinary carboxymethyl-lysine (CML) and methylglyoxal-hydroimidazolone (MG-H1) levels with cardiometabolic parameters in metabolically healthy obese women. Anthropometric, glycemic, cardiovascular, and urinary AGE parameters were measured in 58 metabolically healthy obese women (age: 39.98 ± 8.72 years; body mass index (BMI): 32.29 ± 4.05 kg/m
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.